534 related articles for article (PubMed ID: 35993729)
1. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
2. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
Chen JV; Gahn JC; Nesheim J; Mudd PN
Pharmacoeconomics; 2022 Oct; 40(10):979-988. PubMed ID: 35881325
[TBL] [Abstract][Full Text] [Related]
3. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
Wielage RC; Perk S; Campbell NL; Klein TM; Posta LM; Yuran T; Klein RW; Ng DB
J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
[TBL] [Abstract][Full Text] [Related]
4. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
[TBL] [Abstract][Full Text] [Related]
7. Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder.
Dmochowski RR; Rovner ES; Kennelly MJ; Newman DK; Abedinzadeh L; Snyder D; Thomas E; Haag-Molkenteller C; Rosenberg MT
BMC Urol; 2023 Apr; 23(1):64. PubMed ID: 37095473
[TBL] [Abstract][Full Text] [Related]
8. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
[TBL] [Abstract][Full Text] [Related]
9. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?
Fogaing C; Mossa AH; Campeau L
Curr Urol Rep; 2020 Oct; 21(12):49. PubMed ID: 33090278
[TBL] [Abstract][Full Text] [Related]
10. Vibegron for the treatment of overactive bladder: a comprehensive update.
Gleicher S; Sebesta EM; Reynolds WS; Dmochowski R
Expert Opin Pharmacother; 2022 Sep; 23(13):1479-1484. PubMed ID: 36124780
[TBL] [Abstract][Full Text] [Related]
11. Vibegron: a β
Paton DM
Drugs Today (Barc); 2021 Aug; 57(8):507-517. PubMed ID: 34405208
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.
Aballéa S; Maman K; Thokagevistk K; Nazir J; Odeyemi IA; Hakimi Z; Garnham A; Toumi M
Clin Drug Investig; 2015 Feb; 35(2):83-93. PubMed ID: 25491433
[TBL] [Abstract][Full Text] [Related]
13. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
[TBL] [Abstract][Full Text] [Related]
14. Vibegron, a Novel Potent and Selective β
Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
[TBL] [Abstract][Full Text] [Related]
16. Evaluating vibegron for the treatment of overactive bladder.
Rechberger T; Wróbel A
Expert Opin Pharmacother; 2021 Jan; 22(1):9-17. PubMed ID: 32993398
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01.
Tachikawa K; Kyoda Y; Fukuta F; Kobayashi K; Masumori N
Low Urin Tract Symptoms; 2022 Mar; 14(2):109-116. PubMed ID: 34713579
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
19. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.
Wada N; Mizunaga M; Abe N; Miyauchi K; Kobayashi S; Ohtani M; Tsunekawa R; Nagabuchi M; Morishita S; Ohyama T; Yamaguchi S; Iuchi H; Noda T; Saga Y; Motoya T; Kawakami N; Nishihara M; Numata A; Kakizaki H
World J Urol; 2024 Mar; 42(1):113. PubMed ID: 38431689
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
Shi H; Chen H; Zhang Y; Cui Y
Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
